Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PanChol-100: Safety and Immunogenicity of PanChol: First-in-Human Study of a Novel Live Attenuated Oral Cholera Vaccine

NCT05657782 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT05657782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05657782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PanChol-100: Safety and Immunogenicity of PanChol: First-in-Human Study of a Novel Live Attenuated Oral Cholera Vaccine
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
December 12, 2022
Completion date
December 1, 2025
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholera, cholera vaccine toxicity